On 10 April 2025, Biocon Biologics announced that the FDA has approved its Jobevne™ (bevacizumab-nwgd), biosimilar to Roche/Genentech’s Avastin® (bevacizumab) for intravenous use in treating various cancers including metastatic renal cell carcinoma, metastatic colorectal cancer and cervical cancer.
The first bevacizumab biosimilar approved in the US was Amgen’s Mvasi® in September 2017. There are currently four other bevacizumab biosimilars included in the FDA’s approved drugs database: Amneal’s Alymsys® (April 2022), Bio-Thera/Sandoz’s Avzivi® (December 2023), Celltrion’s Vegzelma™ (September 2022) and Pfizer’s Zirabev® (June 2019).